Established in 1932, the London Clinic is the UK's Most Renowned Independent, Private Hospital Payment to Aclarion for Each Nociscan is Being Increased From the Original Contract Contract Extension Aligns Aclarion and The London Clinic With Engaging Payers to Increase Access to Nociscan for Both Patients and Referring Physicians BROOMFIELD, CO, June 25, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW))), a healthcare technology company that is leveraging biomarkers ...

Established in 1932, the London Clinic is the UK’s Most Renowned Independent, Private Hospital Payment to Aclarion for Each Nociscan is Being Increased From the Original Contract Contract Extension Aligns Aclarion and The London Clinic With Engaging Payers to Increase Access to Nociscan for Both Patients and Referring Physicians BROOMFIELD, CO, June 25, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-41358 ACLARION, INC. (Exact name of registrant as specified in its charter) Delaware 47 ...

LIFEHAB is a randomized controlled trial in Norway comparing lumbar interbody fusion surgery with multidisciplinary rehabilitation Norway is a single-payer national health insurance system LIFEHAB is targeting enrollment to begin in the second quarter of 2024 BROOMFIELD, CO, April 25, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW))),a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________ FORM 10-K _________________ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023. or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41358 ACLARION, INC. (Exact name of registrant as specified in its charter) Delaware 47-3324725 (State or ...

Confirms predictive value of Nociscan for identifying painful discs. Nociscan demonstrated a sensitivity of 100% and a specificity of 80% compared to provocative discography (PD), suggesting Nociscan provides better information to surgeons. BROOMFIELD, CO, March 04, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW))), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians ...

Core Viewpoint - Aclarion, Inc. has successfully closed a public offering of 5,175,000 units, raising approximately $3.0 million before expenses, to support its healthcare technology initiatives focused on chronic low back pain [1][2]. Group 1: Offering Details - Each unit in the offering consists of one share of common stock (or one pre-funded warrant) and two common warrants, with a public offering price of $0.58 per unit [1]. - The common warrants are immediately exercisable at a price of $0.58 per share and will expire five years from the date of issuance [1]. - The offering was conducted under a registration statement declared effective by the SEC on February 26, 2024, and was made only by means of a prospectus [2]. Group 2: Company Overview - Aclarion is a healthcare technology company utilizing Magnetic Resonance Spectroscopy (MRS) and proprietary algorithms to assist physicians in identifying chronic low back pain [4]. - The company's primary product, Nociscan, is a SaaS platform designed to noninvasively differentiate between painful and non-painful discs in the lumbar spine, providing critical insights for treatment optimization [4].

BROOMFIELD, CO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc. ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW))), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, today announced the pricing of its public offering of 5,175,000 units, with each unit consisting of one share of common stock (or one pre-funded warrant in lieu thereof), and two common warrants ...

Aclarion (NASDAQ:ACON) stock is falling on Monday after the healthcare technology company revealed plans for a public offering of its shares.Aclarion intends to offer up to 3,888,888 units in this offering. Each of these units will contain one share of ACON stock and a warrant to acquire another share.The finer details of the public offering still aren’t available. While the company has an assumed price of $1.80 per unit, that’s not concrete. It also hasn’t revealed the exercise price of the warrants in the ...

Table of Contents As filed with the Securities and Exchange Commission on February 23, 2024 Registration No. 333-275989 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 3 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Aclarion, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 8071 47-3324725 (I.R.S. Employer Iden ...